2023
DOI: 10.1016/j.jcpo.2023.100410
|View full text |Cite
|
Sign up to set email alerts
|

Climate toxicity: An increasingly relevant clinical issue in Cancer Care

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 53 publications
0
3
0
Order By: Relevance
“…Interestingly, a bidirectional relationship between climate change and cancer exists. With the term “climate toxicity”, Weadick et al refer to the negative impact of healthcare workers and facilities on the environment, such as carbon production and greenhouse emissions due to both diagnostic and therapeutic interventions [ 46 ].…”
Section: Climate Change In Health and Diseasementioning
confidence: 99%
“…Interestingly, a bidirectional relationship between climate change and cancer exists. With the term “climate toxicity”, Weadick et al refer to the negative impact of healthcare workers and facilities on the environment, such as carbon production and greenhouse emissions due to both diagnostic and therapeutic interventions [ 46 ].…”
Section: Climate Change In Health and Diseasementioning
confidence: 99%
“…Globally this equates to the emissions of the continent of Africa which has 1.5 billion people among 54 countries. Within healthcare, clinical trials have a carbon footprint equivalent to 50% of the annual footprint of Denmark, while the footprint of scienti c discovery has the same annual footprint as Venezuela [5]. Integration of climate smart strategies in the clinical trial arena could mitigate against climate change, and subsequently create and embed a climate responsible ecosystem within clinical trials.…”
Section: Introductionmentioning
confidence: 99%
“…Whether the environmental cost is sufficiently offset by the clinical and other benefits obtained is an area for further evaluation (e.g. if waste associated with the manufacture, distribution and administration of systemic therapeutics is reduced or avoided [Weadick et al, 2023 ]) and as well as the direct and indirect non-financial costs of these tests.…”
mentioning
confidence: 99%